Company Description
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
| Country | United States |
| Founded | 1974 |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 226 |
| CEO | Vishwas Seshadri |
Contact Details
Address: 6555 Carnegie Avenue, 4th Floor Cleveland, Ohio 44103 United States | |
| Phone | 646 813 4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Joseph Walter Vazzano CPA | Chief Financial Officer |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer |
| Brian Kevany Ph.D. | Chief Technical and Scientific Officer |
| Gregory Gin | Vice President of Investor Relations and Corporate Communications |
| Jon Voss | Vice President and Head of Quality |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Chief Commercial Officer |
| Carl Denny | Senior Vice President of Regulatory Affairs |
| Megan Callan | Vice President and Head of Quality |
| Dr. James A. Gow M.B.A., M.D., M.S. | SVice President, Head of Clinical Development and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | SCHEDULE 13G | Filing |
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 7, 2026 | 8-K | Current Report |
| Apr 6, 2026 | SCHEDULE 13G | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 27, 2026 | SCHEDULE 13G | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | 8-K | Current Report |